According to a Bloomberg article, Johnson & Johnson has tentatively agreed with Actelion Ltd. on a price to acquire the biotechnology company, said people familiar with the matter. Discussions are focused on valuing what would be a new unit that would house the research and development assets.
As previously reported, Actelion’s R&D would be spun off into a new company and its shareholders would be able to keep some stock in that business, sources said. Before the latest negotiations started in late December, J&J had made an offer for Actelion valued at more than $28 billion.
Read the Bloomberg article